Announcement
28 Sep 2021
On 28 September 2021, the EIB provided financing worth EUR 15 million (USD 18 million) to support Dutch company Xeltis' research and development (R&D) investments related to cardiovascular therapy and implantable cardiovascular devices.
Source
Number of interventions
2
2 certainly harmful
0 likely harmful
0 liberalising
Implementation date
28 Sep 2021
Revocation date:
No revocation date
See all
This state act is not part of any Thread yet.